Quarterly ResultNov 6, 2026, 09:01 AM
Immunocore Q3 Net Revenues $102.2M; TEBE-AM Trial Enrolled
AI Summary
Immunocore Holdings plc reported Q3 2026 financial results, with KIMMTRAK net revenues at $102.2 million, contributing to $324.8 million year-to-date. The company announced the completion of enrollment for its Phase 3 TEBE-AM trial for advanced cutaneous melanoma, with data anticipated in Q2 2027. Additionally, the first patient was dosed in the Phase 1 trial for IMC-S118AI, an autoimmune candidate for type 1 diabetes. While net revenues showed a slight decrease year-over-year for the quarter, the year-to-date net loss improved significantly. The company ended the quarter with $901.3 million in cash, cash equivalents, and marketable securities.
Key Highlights
- KIMMTRAK net revenues reached $102.2M in Q3 2026, with $324.8M year-to-date.
- Phase 3 TEBE-AM trial for advanced cutaneous melanoma completed enrollment; topline data expected Q2 2027.
- First patient dosed in Phase 1 trial of IMC-S118AI, a tissue-specific autoimmune candidate for type 1 diabetes.
- Q3 2026 net loss was $14.2M ($0.28 loss per share), compared to $0.2M ($0.00 loss per share) in Q3 2025.
- Year-to-date net loss for 2026 was $2.1M ($0.04 loss per share), compared to $5.5M ($0.11 loss per share) in 2025.
- Cash, cash equivalents, and marketable securities totaled $901.3M as of September 30, 2026.
Price Impact
More from IMCR